163 episodes

Molecule to Market takes you inside the contract outsourcing space with industry insights and thoughts direct from the brains of the people that make the headlines (just think of your favourite podcast and that’s what we’re doing, but with drug supply chain shortages instead of unsolved crimes and life science leaders instead of sports stars). Talking everything from pharmaceutical contract research, development and manufacturing to clinical trial packaging, logistics and technology – Molecule to Market is a vital shot of infotainment for anyone who wants in on outsourcing.

Molecule to Market: Inside the outsourcing space Raman Sehgal

    • Science
    • 5.0 • 31 Ratings

Molecule to Market takes you inside the contract outsourcing space with industry insights and thoughts direct from the brains of the people that make the headlines (just think of your favourite podcast and that’s what we’re doing, but with drug supply chain shortages instead of unsolved crimes and life science leaders instead of sports stars). Talking everything from pharmaceutical contract research, development and manufacturing to clinical trial packaging, logistics and technology – Molecule to Market is a vital shot of infotainment for anyone who wants in on outsourcing.

    One-hour special: Meet the next big thing in obesity

    One-hour special: Meet the next big thing in obesity

    In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with Arvid Söderhall, CEO at Empros Pharma.

    Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Arvid, covering:

    The personal story of a pediatrician treating an obese child that led to the creation of Empros Pharma and its lead asset

    The 10-year journey from an idea to a successful Phase IIb trial... and what it felt like to reach the magic milestone

    Critical characteristics required for a small pharma leader, and why CEOs stand and fall with their data

    The ins and outs of a CDMO selection process for Phase 3 trials and the commercial launch for a global drug to complement GLP-1 products

    How the investor climate has changed in the last 1-2 years... and how it has it turned upside down in the hot obesity space

    Arvid joined Empros as a project manager in 2013, during the company’s foundational phase, before the EMP16 project was named. He quickly ascended to CEO, steering Empros to prioritize its founders and inventors while leveraging a strong network of contacts and leading Empros to a phase 3-ready project that surpassed initial expectations.

    He holds a Ph.D. in Physical Chemistry with a specialization in Computational Chemistry. He then completed a postdoctoral fellowship in Berlin, marking his first engagement with the pharma industry and filing a first patent, introducing a foray into biotech entrepreneurship. Subsequently, Arvid worked at Stockholm-based biotech ‘Sidec,’ focusing on cryo-electron microscopy of proteins. Despite the premature technology leading to Sidec’s closure, the foundational concept later earned a Nobel Prize, underscoring the importance of timing in innovation.

    Please subscribe, tell your industry colleagues, and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!

    Molecule to Market is sponsored and funded by ramarketing, an international marketing, design, digital, and content agency helping companies differentiate, get noticed, and grow in life sciences.

    • 1 hr 6 min
    M&A Roundtable and 2024 Predictions

    M&A Roundtable and 2024 Predictions

    In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with:
    Sabina Ouimet-Storrs, Principal at GHO Capital Partners
    James West, Managing Director at Lincoln International
    Derek Hennecke, investor and board member in biopharma and cell therapy manufacturing
    Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology ecosystem with his guests, covering:
    The year of the failed process in 2023...
    Which sub-segments of the pharma services ecosystem are hot right now?
    A myriad of buys and builds, carve-outs, and platform deals
    An optimistic outlook for the year ahead... despite some significant market headwinds
    Please subscribe, tell your industry colleagues, and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!
    Molecule to Market is sponsored and funded by ramarketing, an international marketing, design, digital and content agency helping companies differentiate, get noticed and grow in life sciences.

    • 57 min
    Transforming a family pharma firm

    Transforming a family pharma firm

    In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with Elisabeth Stampa, President Medicines for Europe and Board Chair at Medichem.
     
    Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Elisabeth, covering:
    She took the reigns of the family pharmaceutical firm from her father
    The struggle of turning around the business through rationalization and divestment and critical lessons learned from a tricky time
    Re-building into a multi-national, $140m+ API and FDF CDMO with flexibility at its core
    Insights into future trends will impact our space, including the aging population, reliance on Asia, and the need for patient affordability to access medicines
    With over twenty years in the industry and an experienced business leader with a track record in growing and transforming businesses, Elisabeth serves on the Board of Medichem SA. She has been the former CEO of Medichem SA., transforming a pure API company into a competitive vertical integrated player.
    A pharmacy graduate by trade, she also serves on the Board of Trustees at the IQS in Barcelona and is President Medicines for Europe. Elisabeth has been an active member of international associations throughout her professional career and advocates for legislative changes that improve patient accessibility and strengthen the European industry globally.
    Please subscribe, tell your industry colleagues, and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!
    Molecule to Market is sponsored and funded by ramarketing, an international marketing, design, digital, and content agency helping companies differentiate, get noticed, and grow in life sciences.
     

    • 43 min
    From MassBio... to the world

    From MassBio... to the world

    In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with Kendalle Burlin O’Connell, CEO and President of MassBio.
     
    Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Kendalle, covering:
    The story behind how Massachusetts became one of the biggest biotech clusters in the world and why this ecosystem has such an energy
    Kendalle’s non-linear journey into MassBio and how she made an impact (and ruffled some feathers)
    How she navigated her way to the top of MassBio, including lessons learned along the way and dealing with her inner voice
    Her optimistic sentiment for 2024 and the broader impact on global life sciences
    Kendalle leads the organization's strategic direction and drives policy advocacy for the industry to ensure that Massachusetts life sciences companies have the best environment possible to research, develop, manufacture, and commercialize breakthrough therapies and cures for people worldwide. Pursuing innovation and delivering for members are the hallmarks of Kendalle’s more than 15 years at MassBio, including the launch of several multi-year initiatives focused on realizing a diverse and equitable life sciences industry, supporting the continued growth and sustainability of the sector throughout Massachusetts, and providing resources and solutions to companies across the industry value chain.
    A lawyer by trade, she has earned a spot on the Boston Business Journal’s 2023 Power 50: Movement Makers list is ranked number 33 on Boston Magazine’s 2023 list of The 150 Most Influential Bostonians, a 2022 recipient of the Cambridge Chamber of Commerce Inspire Award recognizing outstanding women leaders in the Cambridge community, a 2022 Boston power player as named by Axios, a 2021 executive fellow in the inaugural class of the Civic Action Project Collaborative, and a 2019 Boston Business Journal 40 under 40 honoree which acknowledges a leader’s impact on Massachusetts’ industries.
    Please subscribe, tell your industry colleagues, and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!
    Molecule to Market is sponsored and funded by ramarketing, an international marketing, design, digital, and content agency helping companies differentiate, get noticed and grow in life sciences.

    • 55 min
    From banking to biotech

    From banking to biotech

    Founder of the Center for Breakthrough Medicines - now part of SK Pharmteco.

    Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Audrey, covering:

    How a career in real estate financial services led her to the world of cell & gene therapy

    The story of the creation of the Center for Breakthrough Medicines to its eventual sale and ‘fit’ with SK Pharmteco

    Why Philadelphia’s 'Cellicon Valley' is becoming one of the hottest life science clusters in the US

    Timeless tips on fundraising, networking and having a go for young people

    Her view on the market outlook for 2024 and beyond

    Audrey is a serial entrepreneur, having founded three startups that have exceeded valuations above $1 billion. As Founder of the Center for Breakthrough Medicines, Audrey successfully launched the company, attracted 400 employees from around the globe, raised over $500 million in capital, closed a 15-year $100 million joint venture with the University of Pennsylvania’s Gene Therapy Program, and sold the company to SK Pharmteco.

    Before launching CBM, Audrey founded Discovery Labs, which grew into the largest privately held life science real estate portfolio in the United States. She spent two decades as an executive in private equity, increasing assets under management to over $100 billion.

    Awards have included being selected as the Top Trailblazer in Biotech, Most Influential Philadelphian, Titan 100 (2x), Healthcare Innovation Leader, and Woman of Influence. She is a renowned keynote speaker specializing in Cell and Gene Therapy, DEI initiatives, 'Cellicon Valley', and building bio innovation hubs.

    Please subscribe, tell your industry colleagues, and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!

    Molecule to Market is sponsored and funded by ramarketing, an international marketing, design, digital, and content agency helping companies differentiate, get noticed and grow in life sciences.

    • 47 min
    Dealing with downturns... and the menopause.

    Dealing with downturns... and the menopause.

    In this episode of Molecule to Market, you’ll go inside the outsourcing space of the global drug development sector with Denise Bowser, Co-Founder and Commercial Director of Onyx Scientific.
    Your host, Raman Sehgal, discusses the pharmaceutical and biotechnology supply chain with Denise, covering:
    The founding story of Onyx and helping the company gain traction in the early years
    A lesson in M&A - being acquired as a great business and being allowed to thrive as a great business
    The non-secret, simple secret sauce of retaining and growing clients over 20 years
    Functioning as a founder while feeling the force of Menopause... and timely advice for others in the workplace
    Advice for dealing with the downturn - diversification, doubling down on your core competence and customer care
    Having founded Onyx Scientific in 2000, Denise has grown the business into a multi-million dollar CDMO with over 100 employees supporting clients in delivering their clinical programs in the pharmaceutical sector. With over 25 years of experience working with clients globally, Denise has built a successful business built on relationships & trust.
    Denise plays golf in her spare time with a handicap of 16 & is an active member of her club, playing competitively for the team & loves getting out to nature, more recently discovering cold dipping & going on road trips in her campervan.
     
    Please subscribe, tell your industry colleagues, and join us in celebrating and promoting the value and importance of the global life science outsourcing space. We’d also appreciate a positive rating!
     
    Molecule to Market is sponsored and funded by ramarketing, an international marketing, design, digital, and content agency helping companies differentiate, get noticed and grow in life sciences.
     

    • 47 min

Customer Reviews

5.0 out of 5
31 Ratings

31 Ratings

JCHOT$$ ,

Great podcast

Really enjoy listening to the content on this show and hearing all of the amazing work happening in this space.

Maryhuston ,

Awesome!

Truly awesome to listen Raman’s shows. He brings out the best of the bests. Thoroughly enjoy his show! Good luck Raman!

C-Lo-77 ,

Great insights!

Raman does a wonderful job with capturing insights across the industry and with experts.

Top Podcasts In Science

Hidden Brain
Hidden Brain, Shankar Vedantam
Radiolab
WNYC Studios
Ologies with Alie Ward
Alie Ward
Something You Should Know
Mike Carruthers | OmniCast Media | Cumulus Podcast Network
StarTalk Radio
Neil deGrasse Tyson
Sasquatch Chronicles
Sasquatch Chronicles - Bigfoot Encounters

You Might Also Like

Business Of Biotech
Matt Pillar
The Readout Loud
STAT
HBR IdeaCast
Harvard Business Review
The World in Brief from The Economist
The Economist
The Knowledge Project with Shane Parrish
Farnam Street
WorkLife with Adam Grant
TED